IMS® DIAREG Diabetes Registry – Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus

Overview

This observation plan outlines the approach to build a diabetes registry to collect data on daily routine of treatment of Type 2 Diabetes Mellitus.

Full Title of Study: “Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2016

Detailed Description

The choice to establish such a (general and specific) disease patient registry was based on several scientific and practical considerations as described in the AHRQ user's guide: registries for evaluating patient outcomes (www.ahrq.gov, 2007). From a public health point of view, such a register should monitor naturalistic (i.e., unbiased) use of diabetes treatment in the community and should primarily guide and assist medical professionals to make optimal choices in combating diabetes. The primary focus of this registry is therefore to monitor the medical and lifestyle treatment of diabetes in order to enable comparison of different treatment options and to provide data for future discussions of optimal treatment.

Interventions

  • Drug: antidiabetic treatment (ATC A10B)

Arms, Groups and Cohorts

  • Type 2 Diabetes Mellitus
    • Patients with antidiabetic treatment for Type 2 Diabetes Mellitus

Clinical Trial Outcome Measures

Primary Measures

  • routine treatment data (composite of e.g. diagnostics, kind and dosage of pharmacological diabetes treatment)
    • Time Frame: From date of registration every 3 months until end of study (up to 120 months)
    • The objective of the project is to develop a sustainable Type 2 Diabetes Mellitus (T2DM) registry to collect daily routine treatment data (e.g. diagnostics, kind and dosage of pharmacological diabetes treatment) to provide a better understanding of the disease specific epidemiology, treatment patterns, patient relevant outcomes, patient subgroups, specifically among patients with Type 2 Diabetes Mellitus. Further DDG (“Deutsche Diabetes Gesellschaft”) guideline adherence and economic aspects of diabetes treatment should be evaluated on the basis of this registry data.

Participating in This Clinical Trial

Inclusion Criteria

  • Provision of signed written informed consent – Age of 18 years or older – Diagnosis of Type 2 Diabetes Mellitus (T2DM) Exclusion Criteria:

Only patients who don't fulfill the inclusion criteria will be excluded. There will be no further possibility for the treating physician to exclude individual patients.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • IMS HEALTH GmbH & Co. OHG
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Stephan Martin, Prof. Dr., Study Chair, Verbund der Katholischen Kliniken Düsseldorf (VKKD) Westdeutschen Diabetes- und Gesundheitszentrum (WDGZ)

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.